Sangart (Sa Diego, CA) a clinical-stage biopharmaceutical focused on perfusion of ischemic tissue and targeted oxygen delivery in the capillaries, closed a $50M Series G financing. Participants include Leucadia.

Merrimack Pharmaceuticals (Cambridge, MA) clinical-stage biotechnology company focused on cancer, closed a $60M Series F financing. Participants include Credit Suisse First Boston, Next Funds, Crocker Ventures, HNI Holdings, Noonday Asset Management, TPG-Axon Capital, Jennison Associates and WT Investment Advisors Fund.

XDx (Brisbane, CA) a commercial-stage molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, closed a $14.4M Series G financing. Participants include Bristol Myers Squibb (NYSE: BMY), Burrill Venture Capital, DAG Ventures, Integral Capital Partners, Integral Capital Partners, Kleiner Perkins Caulfield & Byers, New Leaf Venture Partners and TPG [...]

Ironwood Pharmaceuticlas (Cambridge, MA) a clinical-stage company focused on therapeutics for constipation and irritable bowel syndrome, closed a $50M Series G financing. Participants include Morgan Stanley Investment Management, Ridgeback Capital, Sigma Capital Management, Jennison Associates, Maverick Capital and Paperboy Ventures.

VIRxSYS Corporation (Gaithersburg, MD), who is developing genetic therapies for HIV and cancer, closed a $20M Series G round of financing, the company has raised a total of $87M to date. The financing will be used to support research and clinical programs including VRX496, a gene-based immunotherapy for the treatment of HIV. Phase II clinical [...]